Overview

Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to evaluate the clinical efficacy of scheduled versus free reduction of steroid treatment in patients with active RA treated with adalimumab + MTX
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Abbott
Treatments:
Adalimumab
Methotrexate
Criteria
Inclusion Criteria:

- Subject is age 18 or older and in good health (Investigator discretion) with a recent
stable medical history

- Subject has a diagnosis of rheumatoid arthritis as defined by the 1987-revised ACR
criteria

Exclusion Criteria:

- Subject considered by the investigator, for any reason, to be an unsuitable candidate
for the study

- Female subject who is pregnant or breast-feeding or considering becoming pregnant